open access

Vol 4, No 4 (2015)
Review articles (submitted)
Published online: 2015-10-16
Get Citation

Does in patients with type 2 diabetes and renal failure treated with dialysis can be used to treat blockers DPP-4?

Władysław Grzeszczak, Miroslaw Śnit
DOI: 10.5603/DK.2015.0016
·
Diabetologia Kliniczna 2015;4(4):152-157.

open access

Vol 4, No 4 (2015)
Review articles (submitted)
Published online: 2015-10-16

Abstract

Diabetes is a scourge beginning of the XXI century. Diabetes leads to the development of late complications with reduce the quality of life and reduce the expected survival curve. In the course of diabetes many subjects come to develop ESRD. These patients are then treated with renal replacement therapy, especially hemodialysis. We just give the questions: 1. does in patients with type 2 diabetes treated with hemodialysis may be used in the treatment of blockers dipeptidyl peptidase-4 (DPP-4 blockers)? and 2. what is the effect of such therapeutic treatment?

At the present time worldwide available are 7 blockers DPP-4. In Poland, patients have access only to 4 of them (sitagliptyn, vildagliptin, saxagliptin and linagliptyn). It should be emphasized that these drugs from the group of DPP-4 blockers may be used in patients with type 2 diabetes on hemodialysis. The paper discusses the properties of individual drugs in this group, and then presents the effectiveness of DPP-4 blockers in patients with type 2 diabetes treated with hemodialysis, both alone and in combination therapy.

In the following part of the study presents the impact on other parameters of glucose metabolism and shows anti-inflammatory effect and tolerability and safety measures DPP-4 blockers.

Abstract

Diabetes is a scourge beginning of the XXI century. Diabetes leads to the development of late complications with reduce the quality of life and reduce the expected survival curve. In the course of diabetes many subjects come to develop ESRD. These patients are then treated with renal replacement therapy, especially hemodialysis. We just give the questions: 1. does in patients with type 2 diabetes treated with hemodialysis may be used in the treatment of blockers dipeptidyl peptidase-4 (DPP-4 blockers)? and 2. what is the effect of such therapeutic treatment?

At the present time worldwide available are 7 blockers DPP-4. In Poland, patients have access only to 4 of them (sitagliptyn, vildagliptin, saxagliptin and linagliptyn). It should be emphasized that these drugs from the group of DPP-4 blockers may be used in patients with type 2 diabetes on hemodialysis. The paper discusses the properties of individual drugs in this group, and then presents the effectiveness of DPP-4 blockers in patients with type 2 diabetes treated with hemodialysis, both alone and in combination therapy.

In the following part of the study presents the impact on other parameters of glucose metabolism and shows anti-inflammatory effect and tolerability and safety measures DPP-4 blockers.

Get Citation

Keywords

diabetes, renal failure, hemodialysis, blockers DPP-4

About this article
Title

Does in patients with type 2 diabetes and renal failure treated with dialysis can be used to treat blockers DPP-4?

Journal

Clinical Diabetology

Issue

Vol 4, No 4 (2015)

Pages

152-157

Published online

2015-10-16

DOI

10.5603/DK.2015.0016

Bibliographic record

Diabetologia Kliniczna 2015;4(4):152-157.

Keywords

diabetes
renal failure
hemodialysis
blockers DPP-4

Authors

Władysław Grzeszczak
Miroslaw Śnit

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl